Dr. Reddy's Laboratories (RDY) to Release Earnings on Wednesday

Dr. Reddy's Laboratories (NYSE:RDY) will be posting its quarterly earnings results before the market opens on Wednesday, October 28th. Individual interested in participating in the company’s earnings conference call can do so using this link.

Dr. Reddy's Laboratories (NYSE:RDY) last posted its earnings results on Wednesday, July 29th. The company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.42 by $0.04. The firm had revenue of $585.00 million during the quarter. Dr. Reddy's Laboratories had a return on equity of 18.88% and a net margin of 10.26%. On average, analysts expect Dr. Reddy's Laboratories to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Dr. Reddy's Laboratories stock opened at $66.90 on Tuesday. The company has a current ratio of 1.66, a quick ratio of 1.17 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $11.09 billion, a PE ratio of 44.01 and a beta of 0.41. Dr. Reddy's Laboratories has a 12 month low of $33.33 and a 12 month high of $73.50. The stock has a 50-day moving average price of $67.22 and a two-hundred day moving average price of $57.39.

Several research firms have commented on RDY. Bank of America upgraded Dr. Reddy's Laboratories from a “neutral” rating to a “buy” rating in a research report on Friday, September 18th. Investec upgraded Dr. Reddy's Laboratories from a “sell” rating to a “hold” rating in a research report on Friday, September 18th. Barclays increased their target price on Dr. Reddy's Laboratories from $45.00 to $53.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. ValuEngine upgraded Dr. Reddy's Laboratories from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. Finally, BofA Securities upgraded Dr. Reddy's Laboratories from a “neutral” rating to a “buy” rating in a research report on Friday, September 18th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $53.00.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide.

Further Reading: Pattern Day Trader

Earnings History for Dr. Reddy's Laboratories (NYSE:RDY)

Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.